Thinking of joining a study?

Register your interest

Become a volunteer?

NCT03850366 | RECRUITING | Hematological Malignancy

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Sponsor:

Henry Ford Health System

Information provided by (Responsible Party):

With Farhan

Brief Summary:

Now haplo stem cell transplant using bone marrow or peripheral blood is becoming more feasible with better regimens to prevent graft versus host disease (GVHD) like post transplant cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been shown to inhibit dendritic cells maturation and function and possesses a number of other favorable immunomodulatory effect that can prevent GVHD and help enhance immune reconstitution. this study is to assess the engraftment rate in patients with hematologic malignancies who need allogeneic stem cell transplant but do not have a suitable matched related or unrelated stem cell donor and will get T-cell replete HLA-Haploidentical allogeneic peripheral stem cell transplantation using post transplant Cyclophosphamide and bortezomib

Condition or disease

Hematological Malignancy

Intervention/treatment

Bortezomib

Phase

PHASE2

Study Type : INTERVENTIONAL
Estimated Enrollment : 15 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib Following Fludarbine/Melphalan/Total Body Irradiation Conditioning Regimen
Actual Study Start Date : 2016-03-08
Estimated Primary Completion Date : 2027-01-01
Estimated Study Completion Date : 2027-01-01

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * 18-65 years old patient lacking a matched related donor or unrelated donor but have a related haploidentical donor (\
  • * Candidate for stem cell transplant in a malignant hematological condition
  • * Karnofsky Performance Scale 0-1
  • * Available donor able to undergo a Peripheral blood stem cells collection
  • * Bilirubin \
  • * Serum creatinine clearance \>/=60 ml/min (calculated with Cockroft-Gault formula)
  • * Diffusing capacity for carbon monoxide (DLCO) \>/= 45% predicted corrected for hemoglobin.
  • * Left ventricle ejection fraction \> 40%.
  • * Patient or patient's legal representative, parent(s) or guardian should provide written informed consent.
Exclusion Criteria
  • * Adult who has a suitable related or unrelated donor or cord units available for transplant. Suitable donors include 8/8 (HLA-A,B,C and DR, with all loci high-resolution typing) or 7/8 related or unrelated donor available within 42 days of search initiation
  • * HIV positive; active hepatitis B or C
  • * Patients with active uncontrolled infections.
  • * Liver cirrhosis
  • * Uncontrolled central nervous system involvement by tumor cells
  • * Positive Beta Human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.
  • * Inability to comply with medical therapy or follow-up
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

Location Details

NCT03850366

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Road cancer

Henry Ford hospital

Detroit, Road cancer, United States, 48202